Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974581 | 1.00 | REN (0.52) | REN | |
| SCHEMBL8229073 | 0.88 | REN (0.54) | REN | |
| SCHEMBL14476482 | 0.88 | REN (0.54) | REN | |
| SCHEMBL3757544 | 0.87 | REN (0.55) | REN | |
| SCHEMBL8228765 | 0.87 | REN (0.52) | REN | |
| SCHEMBL4300111 | 0.87 | REN (0.52) | REN | |
| SCHEMBL4300113 | 0.87 | REN (0.52) | REN | |
| SCHEMBL29375920 | 0.87 | REN (0.52) | REN | |
| SCHEMBL220327 | 0.87 | REN (0.55) | REN | |
| SCHEMBL188719 | 0.87 | REN (0.52) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2013-11-21 | — | — | US | disclosed |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2013-11-21 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2225200-B1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS BV (NL) | 2013-10-16 | — | — | EP | disclosed |
| EP-2225200-B1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS BV (NL) | 2013-10-16 | — | — | EP | disclosed |
| WO-2011151442-A2 | PROCESS FOR PRODUCING ALISKIREN | CHEMO IBERICA, S.A. (ES) | 2011-12-08 | — | — | WO | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | VITAE PHARMACEUTICALS, INC | 2010-11-25 | — | — | US | disclosed |
| WO-2009080773-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2007123718-A1 | 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES | VITAE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | REN, AGTR1, AGTR2 | REN 1/4885 |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | REN 1/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | REN 1/4885 |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.